Amanta Healthcare Reports Q1FY27 Results; Highlights Revenue Growth Amid Margin Moderation and Strategic Capacity Expansion Plans
Amanta Healthcare Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported steady revenue growth while facing pressures on margins due to rising operational costs and increased finance charges related to new financing initiatives.The detailed financial performance comparing Q1FY27 with Q1FY26 is provided below:
| Financial Metric (in Rs. Cr.) | Q1FY27 | Q1FY26 |
|---|---|---|
| Revenue | 68.80 | 65.31 |
| EBITDA | 15.18 | 15.85 |
| EBITDA Margin % | 22% | 24% |
| PAT | 3.31 | 3.50 |
| PAT Margin % | 4.8% | 5.3% |
Operational Stability and Profitability Impact
Amanta achieved a 5.4% year-on-year (YoY) revenue growth in Q1 FY27, reaching ₹68.8 crore, driven by improvements in the product mix and better price realizations on an existing capacity base.
Operationally, EBITDA for Q1FY27 stood at INR 15.2 Cr (including other income), compared to INR 15.9 cr in the corresponding period last year. However, the company noted a moderation of EBITDA margins to 22% from 24%, attributing this decline to higher costs related to raw materials, employee expenses, and other operating expenditures.
Profitability was impacted by increased finance costs associated with a new Solar Term Loan. Consequently, PAT for Q1FY27 came in at INR 3.3 cr, representing a 5.6% YoY decrease from INR 3.5 cr, resulting in a PAT margin of 4.8%.
Strategic Capacity Expansion Drives Future Outlook
Despite these cost and financing headwinds, Amanta is strategically progressing with major capacity expansion projects to support future growth. The Steriport plant is anticipated to be commissioned by Q2FY27. Furthermore, the SVP (Sterile Vial/Vial Product) expansion is targeted for completion in Q4 FY27.
These initiatives, alongside a captive solar power plant project, are expected to significantly enhance manufacturing capacity, improve cost efficiency, and build operating leverage over the coming years.
Management Commentary
Bhavesh Patel, Chairman and Managing Director of Amanta Healthcare Limited, commented on the quarterly performance, stating that Q1FY27 marked a period of steady performance with revenue growing 5.4% YoY.
"EBITDA stood at ₹15.2 crore, including other income, despite higher raw material, employee cost and other operating costs," Patel noted. "PAT was impacted largely by higher finance costs."
He added that the company views the coming quarters as presenting exciting growth opportunities. The completion of the SteriPort facility in Q2FY27 and the SVP expansion in Q4 FY27 provide significant headroom for future scale. The progress on these initiatives is bolstering confidence in achieving enhanced profitability and sustainable growth across both domestic and export markets, with the captive solar power project supporting cost efficiencies.
About Amanta Healthcare Limited
Amanta is a pharmaceutical company engaged in the development, manufacturing, and marketing of sterile liquid products, including large volume parenteral (LVPs) and small volume parenteral (SVPs). The company utilizes advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. Amanta serves six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions.
AMANTA Stock Price Movement
Today, the stock settled positively in post-market trading, edging up by 1.91% to close at ₹173. The security saw a total traded volume of 38,451 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.